Amalya Sargsyan: Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC?

Amalya Sargsyan, Medical Oncologist at the Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:

“Narek Shaverdian, among other experts, shared new promising data from phase II study on the role of Stereotactic body radiation therapy (SBRT) addition to standard of care (SOC) for Non-small cell lung cancer (NSCLC) and Breast c-r oligoprogression.

• SBRT shows promise as an addition to SOC in NSCLC, offering a fourfold increase in PFS. SBRT plus SOC group showed Progression-free survival (PFS) of 10.0 months versus 2.2 months in SOC-only group (HR 0.41, 95%CI 0.22-0.75; p=0.0039)
• No significant PFS difference with SBRT plus SOC for breast cancer.

Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC? Make sure to read the full article for more details.”

Source: Amalya Sargsyan/LinkedIn